Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14898394 | 1.00 | ALOX15 (0.36) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL25908987 | 0.95 | ALOX15 (0.38) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL9114925 | 0.87 | ALOX15 (0.36) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL24305739 | 0.86 | MEN1 (0.37) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL25908972 | 0.86 | KDM4E (0.33) | KDM4EMAPK1HIF1APAOX | |
| SCHEMBL20857570 | 0.84 | — | — | |
| SCHEMBL10078923 | 0.79 | ALOX15 (0.38) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL6424463 | 0.77 | ALOX15 (0.36) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL20878389 | 0.75 | — | — | |
| SCHEMBL25908989 | 0.74 | KDM1A (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230119612-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| EP-3052121-B1 | WNT COMPOSITIONS AND METHODS FOR PURIFICATION | UNIV LELAND STANFORD JUNIOR (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20230037284-A9 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-20220000968-A1 | PEPTIDOMIMETIC MACROCYCLES | HOFFMAN-LA ROCHE, INC. | 2022-01-06 | — | — | US | disclosed |
| US-20210363189-A1 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS INC (US) | 2021-11-25 | — | — | US | disclosed |
| US-20210299211-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | AILERON THERAPEUTICS, INC. | 2021-09-30 | — | — | US | disclosed |
| US-11091522-B2 | Peptidomimetic macrocycles and uses thereof | AILERON THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-11008366-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10967042-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-10905739-B2 | Peptidomimetic macrocycles and formulations thereof | AILERON THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20190256559-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2019-08-22 | — | — | US | disclosed |
| US-20190225650-A1 | PEPTIDOMIMETIC MACROCYCLES AND USE THEREOF IN REGULATING HIF1ALPHA | AILERON THERAPEUTICS, INC. | 2019-07-25 | — | — | US | disclosed |
| US-20190185518-A9 | WARHEAD-CONTAINING PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF BFL-1 | AILERON THERAPEUTICS, INC. | 2019-06-20 | — | — | US | disclosed |
| US-10308699-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10227380-B2 | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-10023613-B2 | Peptidomimetic macrocycles as modulators of MCL-1 | AILERON THERAPEUTICS, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180193264-A1 | WNT COMPOSITIONS AND METHODS FOR PURIFICATION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2018-07-12 | — | — | US | disclosed |
| US-9957299-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9937126-B2 | Wnt compositions and methods for purification | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170349638-A1 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225650-A1 | PEPTIDOMIMETIC MACROCYCLES AND USE THEREOF IN REGULATING HIF1ALPHA | HIF1A, HIF1AN, EGLN3 | ALOX15 4192/4885MEN1 1503/4885CYP1A2 3301/4885 |
| US-10023613-B2 | Peptidomimetic macrocycles as modulators of MCL-1 | MCL1, BCL2L1, BCL2L11 | ALOX15 3670/4885MEN1 1135/4885CYP1A2 4470/4885 |
| US-10308699-B2 | Peptidomimetic macrocycles | GHRHR, GHSR, GHITM | ALOX15 4018/4885MEN1 89/4885CYP1A2 4349/4885 |
| US-20230119612-A1 | PEPTIDOMIMETIC MACROCYCLES | TP53, MDM2, MDM4 | ALOX15 4436/4885MEN1 250/4885CYP1A2 4694/4885 |
| US-10905739-B2 | Peptidomimetic macrocycles and formulations thereof | MDM2, TP53, TP53BP1 | ALOX15 4003/4885MEN1 567/4885CYP1A2 4431/4885 |
| US-20170349638-A1 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | TP53, TP53BP1, VHL | ALOX15 4769/4885MEN1 585/4885CYP1A2 4396/4885 |
| US-20230037284-A9 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | BID, FLT3, GRPR | ALOX15 4124/4885MEN1 356/4885CYP1A2 4241/4885 |
| US-20190185518-A9 | WARHEAD-CONTAINING PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF BFL-1 | BCL2L11, BCL2L1, BCL2L13 | ALOX15 4210/4885MEN1 1644/4885CYP1A2 4378/4885 |
| US-20210299211-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | MDM2, TP53, TP53BP1 | ALOX15 4003/4885MEN1 567/4885CYP1A2 4431/4885 |
| US-10227380-B2 | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles | IL33, TPR, CDC37 | ALOX15 2725/4885MEN1 1768/4885CYP1A2 2855/4885 |
| US-20190256559-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | TP53, TP53BP1, MDM2 | ALOX15 4370/4885MEN1 1408/4885CYP1A2 3204/4885 |
| US-11091522-B2 | Peptidomimetic macrocycles and uses thereof | FLT3, BID, GRPR | ALOX15 3714/4885MEN1 376/4885CYP1A2 4151/4885 |
| US-11008366-B2 | Peptidomimetic macrocycles | GLP1R, PROKR1, VIP | ALOX15 3864/4885MEN1 219/4885CYP1A2 4311/4885 |
| US-20220000968-A1 | PEPTIDOMIMETIC MACROCYCLES | TP53, MDM2, MDM4 | ALOX15 4436/4885MEN1 250/4885CYP1A2 4694/4885 |
| US-10967042-B2 | Peptidomimetic macrocycles | TP53, MDM2, MDM4 | ALOX15 4436/4885MEN1 250/4885CYP1A2 4694/4885 |
| US-20180193264-A1 | WNT COMPOSITIONS AND METHODS FOR PURIFICATION | WNT3A, CTNNBL1, WNT1 | ALOX15 2110/4885MEN1 3024/4885CYP1A2 4859/4885 |
| US-20210363189-A1 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | BID, FLT3, GRPR | ALOX15 4124/4885MEN1 356/4885CYP1A2 4241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.